Obesity is an important modifiable factor for pancreatic cancer risk and is linked to increased mortality from PDAC and the promotion of desmoplasia through the action of various adipokines, among which leptin is a candidate that affects chemotherapy effectiveness due to its proinflammatory, proangiogenic, and survival effects [1]. Here, LEP is linked to obesity disorder.